Literature DB >> 7927415

V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig).

M D Kazatchkine1, G Dietrich, V Hurez, N Ronda, B Bellon, F Rossi, S V Kaveri.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7927415     DOI： 10.1111/j.1600-065x.1994.tb00858.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  17 in total

Review 1.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

2.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 3.  Immunity, infection, and nasal disease.

Authors:  S H Yoshida; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 8.667

4.  Intravenous immunoglobulin and immune response.

Authors:  S V Kaveri; M Lecerf; C Saha; M D Kazatchkine; S Lacroix-Desmazes; J Bayry
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Authors:  Namita Misra; Jagadeesh Bayry; Amal Ephrem; Suryasarathi Dasgupta; Sandrine Delignat; Jean-Paul Duong Van Huyen; Fabienne Prost; Sebastien Lacroix-Desmazes; Antonino Nicoletti; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

6.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Authors:  S Kaveri; T Vassilev; V Hurez; R Lengagne; C Lefranc; S Cot; P Pouletty; D Glotz; M D Kazatchkine
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

8.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 9.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

10.  Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases.

Authors:  C Xu; B Poirier; J P Duong Van Huyen; N Lucchiari; O Michel; J Chevalier; S Kaveri
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.